Building the clinical standard for measuring progressive muscle weakness.
Quantitative. Portable. Non-invasive. Painless.
Smaller, more diverse clinical trials.
“We will strive to help accurately assess and monitor the disease condition and then seek to unveil extraordinary progress made by the passionately dedicated clinicians, scientists, caregivers and, most of all, patients who fight neuromuscular and musculoskeletal diseases, each and every day.”
The Promise of
Electrical impedance myography (EIM) is a non-invasive, painless assessment method that quantifies the passive electrical behavior of muscles. It is based on the idea that conductivity and permittivity in a diseased muscle are altered, and these alterations in the muscle can cause changes in the voltage generated.
EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied to an area of tissue across two electrodes and the resulting voltage signals measured across two sense electrodes.
EIM evaluates specific regions of muscle by specifically forcing the current along or across myofibers. It is sensitive to microscopic tissue morphology and composition, including cell atrophy, density, membrane integrity, subcellular structures, and interstitial changes, such as fibrosis, edema, inflammation, and fat deposition.
Importantly, EIM does not require the active participation of the patient, providing quantitative data on functional capability while the muscle and patient remain entirely at rest.
Research Collaborators To Date
National Institutes of Health
Peer-reviewed scientific articles showing EIM sensitivity to disease progression and drug effects, reliability, and ease of use
IRB-approved clinical studies by pharmaceutical companies
Get In Touch
1309 Beacon Street,